NVAX vs. AZN
Compare and contrast key facts about Novavax, Inc. (NVAX) and AstraZeneca PLC (AZN).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NVAX or AZN.
Correlation
The correlation between NVAX and AZN is 0.40, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NVAX vs. AZN - Performance Comparison
Loading data...
Key characteristics
NVAX:
-0.55
AZN:
-0.43
NVAX:
-0.47
AZN:
-0.45
NVAX:
0.95
AZN:
0.94
NVAX:
-0.53
AZN:
-0.38
NVAX:
-1.00
AZN:
-0.66
NVAX:
52.01%
AZN:
15.75%
NVAX:
94.39%
AZN:
23.21%
NVAX:
-98.82%
AZN:
-48.94%
NVAX:
-98.03%
AZN:
-21.35%
Fundamentals
NVAX:
$965.34M
AZN:
$207.93B
NVAX:
$2.75
AZN:
$2.48
NVAX:
2.17
AZN:
26.71
NVAX:
0.00
AZN:
0.89
NVAX:
0.77
AZN:
3.78
NVAX:
49.52
AZN:
5.00
NVAX:
$1.25B
AZN:
$54.98B
NVAX:
$1.11B
AZN:
$44.75B
NVAX:
$536.50M
AZN:
$17.70B
Returns By Period
In the year-to-date period, NVAX achieves a -21.77% return, which is significantly lower than AZN's 5.18% return. Over the past 10 years, NVAX has underperformed AZN with an annualized return of -28.33%, while AZN has yielded a comparatively higher 10.46% annualized return.
NVAX
-21.77%
-1.56%
-12.88%
-51.24%
-32.20%
-28.33%
AZN
5.18%
0.13%
5.95%
-9.92%
7.40%
10.46%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NVAX vs. AZN — Risk-Adjusted Performance Rank
NVAX
AZN
NVAX vs. AZN - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Novavax, Inc. (NVAX) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
NVAX vs. AZN - Dividend Comparison
NVAX has not paid dividends to shareholders, while AZN's dividend yield for the trailing twelve months is around 2.25%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVAX Novavax, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
AZN AstraZeneca PLC | 2.25% | 2.27% | 2.15% | 2.14% | 2.40% | 2.80% | 2.81% | 3.61% | 3.95% | 5.01% | 4.06% | 3.98% |
Drawdowns
NVAX vs. AZN - Drawdown Comparison
The maximum NVAX drawdown since its inception was -98.82%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for NVAX and AZN. For additional features, visit the drawdowns tool.
Loading data...
Volatility
NVAX vs. AZN - Volatility Comparison
Novavax, Inc. (NVAX) has a higher volatility of 29.26% compared to AstraZeneca PLC (AZN) at 8.44%. This indicates that NVAX's price experiences larger fluctuations and is considered to be riskier than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
NVAX vs. AZN - Financials Comparison
This section allows you to compare key financial metrics between Novavax, Inc. and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NVAX vs. AZN - Profitability Comparison
NVAX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Novavax, Inc. reported a gross profit of 652.54M and revenue of 666.66M. Therefore, the gross margin over that period was 97.9%.
AZN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, AstraZeneca PLC reported a gross profit of 11.35B and revenue of 13.59B. Therefore, the gross margin over that period was 83.5%.
NVAX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Novavax, Inc. reported an operating income of 515.51M and revenue of 666.66M, resulting in an operating margin of 77.3%.
AZN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, AstraZeneca PLC reported an operating income of 3.67B and revenue of 13.59B, resulting in an operating margin of 27.0%.
NVAX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Novavax, Inc. reported a net income of 518.65M and revenue of 666.66M, resulting in a net margin of 77.8%.
AZN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, AstraZeneca PLC reported a net income of 2.92B and revenue of 13.59B, resulting in a net margin of 21.5%.